US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VanEck Uranium+Nuclear Energy ETF

78.51

-1.1844-1.49%

Volume:27.95K

Turnover:2.19M

Market Cap:1.01B

PE:- -

High:78.83

Open:78.30

Low:77.43

Close:79.69

Loading ...

Overview Company News Filings

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Press Release: Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Pacific Gas & Electric Holds The Line On Q4 EPS Amid Grid Modernization Push: Details

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®

South Korea ETFs struggle despite country showing 'resiliency' after martial law

What a new uranium-trading platform says about investor interest in nuclear energy

Uranium prices rise after Russia temporarily limits supplies to U.S.

Biden administration unveils plan to triple nuclear energy capacity by 2050

Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NLR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NLR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NLR\",,,,,undefined,":{"symbol":"NLR","market":"US","secType":"STK","nameCN":"VanEck Uranium+Nuclear Energy ETF","latestPrice":78.5056,"timestamp":1746034143161,"preClose":79.69,"halted":0,"volume":27951,"delay":0,"floatShares":12916632,"shares":12916632,"eps":0,"marketStatus":"Trading","change":-1.1844,"latestTime":"04-30 13:30:58 EDT","open":78.3,"high":78.83,"low":77.43,"amount":2187257.4292800003,"amplitude":0.017568,"askPrice":78.63,"askSize":5,"bidPrice":78.3,"bidSize":13,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":79.69,"sharesOutstanding":12741632,"nav":78.97713,"aum":1006297563.39,"bidAskSpread":0.004742,"preHourTrading":{"tag":"盘前","latestPrice":76.3,"preClose":79.69,"latestTime":"09:22 EDT","volume":1272,"amount":100316.208768,"timestamp":1746019349634},"postHourTrading":{"tag":"盘后","latestPrice":79.69,"preClose":79.69,"latestTime":"19:47 EDT","volume":406,"amount":31594.805,"timestamp":1745970464606},"volumeRatio":0.582851,"impliedVol":0.2509,"impliedVolPercentile":0.576},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NLR\",,,,,undefined,":{"symbol":"NLR","floatShares":12916632,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.582851,"shares":12916632,"dividePrice":0.6142,"high":78.83,"amplitude":0.017568,"preClose":79.69,"low":77.43,"week52Low":64.26,"pbRate":"--","week52High":97.89,"institutionHeld":0,"latestPrice":78.5056,"committee":0.444444,"eps":0,"divideRate":0.007824,"volume":27951,"delay":0,"ttmEps":0,"open":78.3,"prevYearClose":81.34,"prevWeekClose":77.98,"prevMonthClose":73.27,"prevQuarterClose":73.27,"fiveDayClose":75.79,"twentyDayClose":74.04,"sixtyDayClose":89.24},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NLR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531303571","title":"BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified","url":"https://stock-news.laohu8.com/highlight/detail?id=2531303571","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531303571?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:30","pubTimestamp":1746012600,"startTime":"0","endTime":"0","summary":"Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study. Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits. Positive delayed-type hypersensitivity   and a favorable Neutrophil-to-Lymphocyte Ratio   linked to longer progression-free survival  in Phase 3 patients. Presence of Circulating Tumor Cells  after patients’ initial Phase 3 treatment supports role as negative prognostic marker . Bria-IMT Phase 3 regimen was well-tolerated with a preferred tolerability profile. “Using biomarkers as powerful instruments to predict patient responsiveness to the Bria-IMT treatment would allow physicians and oncologists to identify potential responders sooner, providing better clinical outcomes and ultimately extending patients’ lives,” stated Carmen Calfa, MD, Clinical Research Lead for the breast site disease group at the University of Miami Miller School of Medicin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-reports-breaker-phase-3-113000083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BCTXW","BCTXZ","BK4097","BK4211","BK4606","NLR","PFS","BCTX","BK4129","BK4195","CAML","OS","TPC","DTH"],"gpt_icon":0},{"id":"2522222180","title":"Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2522222180","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522222180?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":"NEW YORK, March  25, 2025  (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, annou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/25/3048658/0/en/Indaptus-Therapeutics-Chief-Medical-Officer-Roger-Waltzman-M-D-M-B-A-to-Moderate-Panel-at-CMO360-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMF","BK4211","NLR","LENZ","BK4139","BK4606"],"gpt_icon":0},{"id":"2520678244","title":"Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2520678244","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520678244?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:00","pubTimestamp":1742299200,"startTime":"0","endTime":"0","summary":"New trial arm to evaluate safety, dosing and preliminary anti-tumor activity in advanced solid tumors. NEW YORK, March 18, 2025  -- Indaptus Therapeutics, Inc. , a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced toa new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.Jeffrey Meckler, CEO of Indaptus, commented, “This marks a pivotal step forward for Indaptus and our Decoy platform. Preclinical research has consistently shown that Decoy20 works synergistically with a checkpoint inhibitor, and we now have the opportunity to test that in patients for the first time. While this initial phase will focus on safety and tolerability, we are laying the groundwork for what could be a game-changin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/indaptus-therapeutics-initiates-phase-1-120000013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","NLR","LU1169590202.USD","INDP","BK4606","BK4023","LENZ","LU1169589451.USD","PD"],"gpt_icon":1},{"id":"2519386248","title":"Press Release: Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519386248","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519386248?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:30","pubTimestamp":1741865400,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update. -- Company Achieves Key Clinical Milestone with more than 20 Patients. Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20. -- Pharmacodynamic immune activation biomarker and pharmacokinetics profiles. in initial data sets appear to meet or exceed initial expectations. -- Early signs of potential benefit emerge with some patients demonstrating. Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, \"We continue to make significant progress in our Phase 1 trial of Decoy20, and enrolling more than 20 patients in the weekly dosing cohort marks an important milestone. We are particularly encouraged by the emerging clinical data, with some patients in this cohort demonstrating stable disease - an early sign that Decoy20's immune-modulating approach may be having a meaningful impact. With a favorable safety profile observed so far, we are focused on efficiently a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4080","BK4231","BK4139","LENZ","SITC","BK4606","NLR"],"gpt_icon":0},{"id":"2516675441","title":"Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675441","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516675441?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 04, 2025  -- Indaptus Therapeutics, Inc. , a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announced today that it has secured new patent approvals in China, Japan and Israel for its Decoy platform. These patents cover the use of Decoy bacteria compositions for preventing or treating Hepatitis B virus  and human immunodeficiency virus  – two diseases that continue to pose major global health challenges. The patents also extend to combination therapies with a variety of both approved and investigational treatments.Dr. Michael Newman, Founder and Chief Scientific Officer of Indaptus, commented, “The allowance of these patents in key international markets highlights the potential of our Decoy platform in the fight against chronic infectious diseases. With millions of people affected by HBV and HIV worldwide, expanding our intellectual property reinforces the novelty and therapeutic promise of our approach.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/indaptus-therapeutics-expands-patent-portfolio-130000815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4606","NLR","INDP","LENZ","BK4139"],"gpt_icon":0},{"id":"2514579099","title":"Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2514579099","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514579099?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb.  25, 2025  (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infection","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3031951/0/en/Indaptus-Therapeutics-Chief-Scientific-Officer-Dr-Michael-Newman-to-Present-at-the-10th-Annual-Innate-Killer-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4606","NLR","LENZ","SMMF","BK4139"],"gpt_icon":0},{"id":"2511078618","title":"Pacific Gas & Electric Holds The Line On Q4 EPS Amid Grid Modernization Push: Details","url":"https://stock-news.laohu8.com/highlight/detail?id=2511078618","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511078618?lang=en_us&edition=fundamental","pubTime":"2025-02-15 01:30","pubTimestamp":1739554227,"startTime":"0","endTime":"0","summary":"PG&amp;E reports Q4 results in line with consensus, 2024 adjusted EPS up aided by higher investment, plans to support 5.5 GW of new data center demand.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/02/43738960/whats-going-on-with-pacific-gas-electric-shares-on-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NLR","PCG","RNWZ"],"gpt_icon":0},{"id":"2509573283","title":"Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20","url":"https://stock-news.laohu8.com/highlight/detail?id=2509573283","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509573283?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:00","pubTimestamp":1738760400,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 05, 2025  -- Indaptus Therapeutics, Inc.  , a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the Company has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20. This approval will allow the Company to expand its ongoing U.S. clinical trial, INDP-D101, to Canadian sites, broadening patient recruitment and enhancing its clinical research program. The trial will enroll patients in Canada under the current protocol, which involves weekly dosing of Decoy20. Indaptus also plans to submit an amendment to Health Canada to incorporate its upcoming combination trial, which pairs Decoy20 with Beigene’s PD-1 checkpoint inhibitor,tislelizumab.Jeffrey Meckler, CEO of Indaptus, commented, “We are pleased to bring Canadian investigators and patients into our clinical efforts, creating a more diverse and robust data set. Health Canada’s approval followed a c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/indaptus-therapeutics-receives-approval-health-130000809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NLR","INDP","LENZ","BK4139","BK4606"],"gpt_icon":0},{"id":"2501721041","title":"Indaptus Therapeutics Provides Year-End Review and Outlook for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501721041","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501721041?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341200,"startTime":"0","endTime":"0","summary":"Continued Strong Clinical Progress and Planned New Combination Trial Provide Significant Momentum for 2025. NEW YORK, Jan. 08, 2025  -- Indaptus Therapeutics, Inc.  , a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today highlights its accomplishments in 2024 and outlines the Company’s strategic goals for the year ahead.Advancing Decoy20 in Clinical Trials2024 was a year of meaningful progress for Indaptus’ lead clinical candidate, Decoy20, a novel immunotherapy designed to harness both innate and adaptive immune responses. Highlights from the Company’s Phase 1 clinical trial include:. Second Cohort Results : Building on the Company’s November 2023 findings, Decoy20 demonstrated a broad immune response across multiple tumor types in patients, underscoring the platform’s potential as a monotherapy.Weekly-Dose Cohort Initiation : After receiving Safety Review Committee approval, the Company dosed its first patient in the weekly-dose por","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/indaptus-therapeutics-provides-end-review-130000198.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4080","BK4231","BK4139","SITC","NLR","INDP"],"gpt_icon":0},{"id":"2491322908","title":"BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2491322908","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491322908?lang=en_us&edition=fundamental","pubTime":"2024-12-13 20:50","pubTimestamp":1734094200,"startTime":"0","endTime":"0","summary":"BriaCell reports influx of cancer fighting CD8+ “killer” T cell into metastatic breast cancer tumors and lymph organs turning “Cold” tumors and lymph nodes “Hot” on ImmunoPET imaging in cancer patient","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/13/2996746/0/en/BriaCell-2024-SABCS-Poster-Highlights-Ability-of-Bria-IMT-Regimen-to-Increase-Cancer-Fighting-Immune-Cells-in-Metastatic-Breast-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABIL","NLR","CPI","BCTX"],"gpt_icon":0},{"id":"2490212859","title":"BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®","url":"https://stock-news.laohu8.com/highlight/detail?id=2490212859","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490212859?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:50","pubTimestamp":1733921400,"startTime":"0","endTime":"0","summary":"Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the lite","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/11/2995320/0/en/BriaCell-Presents-Unprecedented-Overall-Survival-Data-in-Metastatic-Breast-Cancer-in-Spotlight-Poster-at-2024-SABCS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBC","BK4097","CPI","CNS","BK4135","BK4086","OS","DTH","NLR"],"gpt_icon":0},{"id":"2489445629","title":"South Korea ETFs struggle despite country showing 'resiliency' after martial law","url":"https://stock-news.laohu8.com/highlight/detail?id=2489445629","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489445629?lang=en_us&edition=fundamental","pubTime":"2024-12-06 07:57","pubTimestamp":1733443020,"startTime":"0","endTime":"0","summary":"Investors are also watching France after its government fell this week. This week's ETF Wrap looks at what the recent political turmoil in South Korea and France means for investors.\"The response from both government and civil society\" showed South Korea's \"checks and balances and strength of institutions are strong,\" said Perth Tolle, founder of Life + Liberty Indexes, in an email to MarketWatch. Tolle's Freedom 100 Emerging Markets ETF FRDM - which tracks an index of emerging-market stocks based on personal- and economic-freedom metrics and excludes authoritarian regimes - currently has a 14% weight to South Korea.\"Our methodology results in higher exposure to countries with stronger institutions, rule of law, and checks and balances,\" said Tolle. South Korea provided \"a good test of all those things, and so far, the outcome appears consistent with their allocation in the FRDM index strategy,\" she said, referring to the ticker of the Freedom 100 Emerging Markets ETF.Shares of the fun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OIH","BK4535","FRDM","MFSI","US30Y.BOND","SCY","MOO","US12M.BOND","EMLC","BK4544","US6M.BOND","QQLV","BK4585","MFSB","FLKR","MFSV","MFSG","BK4550","MKOR","RAYE","US7Y.BOND","YGLD","PFXF","NLR","SMH","ARKW","EWQ","US10Y.BOND","ARKF","QBIG","US3Y.BOND","BK4588","ARKK","US5Y.BOND","US2Y.BOND","CORO","EWY","FDN","ARKG","MFSM"],"gpt_icon":1},{"id":"2489940754","title":"What a new uranium-trading platform says about investor interest in nuclear energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2489940754","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489940754?lang=en_us&edition=fundamental","pubTime":"2024-12-06 03:47","pubTimestamp":1733428020,"startTime":"0","endTime":"0","summary":"There's 'clearly a lot of interest in uranium among investors, and this includes retail investors': analyst. Investor interest in nuclear energy is running hot and leading to new products, including the launch this week of a blockchain-based platform that allows traders to buy and sell a tokenized version of uranium.There's \"clearly a lot of interest in uranium among investors, and this includes retail investors,\" said Jonathan Hinze, president at UxC, a nuclear-fuel market information and analysis firm. \"With the outlook for nuclear power and fuel demand growth continuously improving, it's no surprise that investors want to capture the upside potential in this market.\". Still, liquidity and ease of trading on the new platform will be key to its success for investors, he told MarketWatch.\"The appetite for nuclear power is definitely increasing, so there's an uptrend to catch here in terms of interest for and visibility of the assets,\" said Arthur Breitman, co-founder of Tezos, an open-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2249611893.SGD","LU0795875169.SGD","IE00BDGV0183.EUR","LU0950375773.USD","BK4591","LU1732800096.USD","LU0912757837.SGD","LU0823414478.USD","URA","BK4104","IE00B3PB1722.GBP","NLR","LU2237438978.USD","IE00BGHQF631.EUR","LU2506951792.HKD","IE00B3T34201.USD","LU0158827948.USD","LU2506951958.HKD","LU0795875086.SGD","CCJ","CME","IE00BVYPNW00.USD","LU0823414551.USD","BK4112","LU2089284900.SGD","LU2506952170.USD","IE00BVYPNV92.GBP","BK4561","LU0731783394.SGD","LU0823417737.USD","BK4563","LU1599440770.SGD","LU1718418525.SGD","BK4585","LU2294711713.HKD","LU2089283258.USD","LU2133065610.SGD","IE00B42XCP33.USD","LU2347655156.SGD","YLLXF","BK4566","LU0823417653.USD","UROY","LU2023251221.USD","LU1732799900.SGD","LU2506952097.USD","BK4156","LU2357125470.USD","BK4588","LU2506951875.HKD"],"gpt_icon":1},{"id":"2483813255","title":"Uranium prices rise after Russia temporarily limits supplies to U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483813255","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483813255?lang=en_us&edition=fundamental","pubTime":"2024-11-16 01:32","pubTimestamp":1731691939,"startTime":"0","endTime":"0","summary":"zhongguo/E+ via Getty Images Uranium prices rose Friday after Russia announced temporary restrictions on the export of enriched uranium to the U.S., although uranium-related shares trade mixed after moving higher on the initial news. Trading higher: Ur-Energy (URG) +3.6%, Denison Mines (","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1185889689/image_1185889689.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1185889689/image_1185889689.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4295795-uranium-prices-rise-after-russia-temporarily-limits-supplies-to-us","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["URA","BK4156","NLR","BK4588","UEC","URG","BK4585"],"gpt_icon":0},{"id":"2483061988","title":"Biden administration unveils plan to triple nuclear energy capacity by 2050","url":"https://stock-news.laohu8.com/highlight/detail?id=2483061988","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483061988?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:43","pubTimestamp":1731451421,"startTime":"0","endTime":"0","summary":"vchal/iStock via Getty Images The Biden administration announced plans Tuesday to triple U.S. nuclear energy capacity by 2050 as it aims to reach its net-zero emissions goal. Under the plan, the U.S. would deploy an additional 200 GW of new nuclear energy capacity by 2050 through","market":"other","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1270632735/image_1270632735.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1270632735/image_1270632735.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4282612-biden-administration-unveils-plan-to-triple-nuclear-energy-capacity-by-2050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4585","BK4588","URA","NLR"],"gpt_icon":0},{"id":"2482789558","title":"Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology","url":"https://stock-news.laohu8.com/highlight/detail?id=2482789558","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482789558?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:00","pubTimestamp":1731330000,"startTime":"0","endTime":"0","summary":"Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or tar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/11/2978250/0/en/Indaptus-Therapeutics-Pioneering-Research-on-Novel-Immunotherapy-Approach-Published-in-Peer-Reviewed-Frontiers-in-Immunology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NLR","BK4139"],"gpt_icon":0},{"id":"2481904186","title":"Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904186","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904186?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984400,"startTime":"0","endTime":"0","summary":"Data further confirms Company’s “Pulse-Prime” hypothesis. NEW YORK, Nov. 07, 2024  -- Indaptus Therapeutics, Inc.  , a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces compelling safety, pharmacokinetics, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer  2024 annual meeting. The data derive from two cohorts  of Decoy20 single administration and one cohort  of Decoy20 weekly administration in the Company’s ongoing Phase 1 clinical trial. The SITC conference is being held November 6-10, 2024 in Houston, Tex.Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be adminis","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3XXQS3YWdGJ1JC2JJgEReg--~B/aD02MDt3PTIyNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/7ccb73735e7b3453e7f55361e2fdf8ed","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3XXQS3YWdGJ1JC2JJgEReg--~B/aD02MDt3PTIyNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/7ccb73735e7b3453e7f55361e2fdf8ed"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/indaptus-therapeutics-presents-encouraging-interim-130000687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NLR","BK4080","SITC","BK4231","LENZ","BK4139","INDP"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NLR\",params:#limit:5,,,undefined,":[{"date":"2024-12-23","symbol":"NLR","amount":0.6142,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"核能指数ETF-Market Vectors","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"NLR","amount":3.258,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"核能指数ETF-Market Vectors","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"NLR","amount":1.1093,"defaultRemindTime":1671460200000,"name":"核能指数ETF-Market Vectors","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"NLR","amount":1.091,"defaultRemindTime":1640010600000,"name":"核能指数ETF-Market Vectors","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000},{"market":"US","date":"2020-12-21","symbol":"NLR","amount":1.0964,"name":"核能指数ETF-Market Vectors","recordDate":"2020-12-28","payableDate":"2020-12-22","currency":"USD","type":"dividend","dateTimestamp":1608526800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NLR\",market:\"US\",,,undefined,":[{"executeDate":"2015-12-21","recordDate":"2015-12-23","paymentDate":"2015-12-28","value":1.486,"currency":"USD"},{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":1.719,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":1.936,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":1.072,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":1.0964,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NLR\",market:\"US\",delay:false,,,undefined,":{}}}